Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

about

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience Tools to improve clinical trial design in urothelial cancer.

P2860

Q35586693-4B2DA2F0-A48E-41D3-947B-7C6D5D6CCC99 Q46858165-B2B8D5D4-A906-4AD2-865F-F317634A5FC7

P2860

Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

Item

http://www.wikidata.org/entity/Q45718951

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@en

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@nl

type

Item

label

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@en

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@nl

prefLabel

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@en

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@nl

P1476

Relationship between 6- and 9- ...... cisplatin-based chemotherapy.

@en

P2093

Aristotle Bamias

http://www.w3.org/2001/XMLSchema#string

Chia-Chi Lin

http://www.w3.org/2001/XMLSchema#string

Erin Moshier

http://www.w3.org/2001/XMLSchema#string

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

James Godbold

http://www.w3.org/2001/XMLSchema#string

Matthew D Galsky

http://www.w3.org/2001/XMLSchema#string

Noah Hahn

http://www.w3.org/2001/XMLSchema#string

Susan Krege

http://www.w3.org/2001/XMLSchema#string

Thorsten Ecke

http://www.w3.org/2001/XMLSchema#string

William K Oh

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Reporting results of cancer treatment

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Endpoints in phase II trials for advanced non-small cell lung cancer.

Detecting an overall survival benefit that is derived from progression-free survival

P304

3020-3026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28145

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23720197

http://www.w3.org/2001/XMLSchema#string

Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

about

P2860

P2860

Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698